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The Rac-specific guanine nucleotide exchange factor, Tiam1, plays a major role in oncogenicity, tumour invasion and metastasis but its
usefulness as a prognostic marker in human cancer has not been tested yet. In the present study, Tiam1 expression was analysed in
benign secretory epithelium, pre-neoplastic high-grade prostatic intraepithelium neoplasia (HG-PIN) and prostate carcinomas of 60
R0-resected radical prostatectomy specimens by semiquantitative immunohistochemistry. Tiam1 proved significantly overexpressed
in both HG-PIN (Po0.001) and prostate carcinomas (Po0.001) when compared to benign secretory epithelium. Strong Tiam1
overexpression (i.e. X3.5-fold) in prostate carcinomas relative to the respective benign prostatic epithelium was statistically
significantly associated with disease recurrence (P¼0.016), the presence of lymph vessel invasion (P¼0.031) and high Gleason
scores (GS) (i.e. X7) (P¼0.044). Univariate analysis showed a statistically significant association of strong Tiam1 overexpression with
decreased disease-free survival (DFS) (P¼0.03). This prognostic effect of strong Tiam1 overexpression remained significant in
multivariate analysis including preoperative prostate-specific antigen levels, pT stage, and GS (relative risk¼ 3.75, 95% confidence
interval¼1.06–13.16; P¼0.04). Together, our data suggest that strong Tiam1 overexpression relative to the corresponding benign
epithelial cells is a new and independent predictor of decreased DFS for patients with prostate cancer.
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Prostate cancer is a leading cause of cancer death in men in North
America and Western Europe. However, as compared to the high
general risk of prostate cancer (one in six), the risk of death owing
to prostate cancer is one in 30 (Jemal et al, 2003), indicating that
only a fraction of cases would lead to cancer-related death if left
untreated. Consequently, there is a great need for markers, which
accurately predict the risk of disease progression in patients with
prostate cancer and thus allow appropriate treatment planning.
However, prognostic markers typically used so far, including
tumour stage, Gleason score (GS), and the serum level of prostate-
specific antigen (PSA) are not sufficiently precise to do so (Ross
et al, 2003).
The guanine nucleotide exchange factor, Tiam1, specifically
activates the Rho-like GTPase Rac (Michiels et al, 1995) and
Tiam1-Rac signaling affects cell migration (Hordijk et al, 1997;
Sander et al, 1998), invasion (Michiels et al, 1995; Keely et al, 1997;
Engers et al, 2001), and metastasis (Habets et al, 1994) of tumour
cells. Moreover, Tiam1 and Rac have been implicated in oncogenic
transformation of cells. Thus, N-terminal truncation of the Tiam1
protein activates its oncogenic potential in NIH3T3 cells (van
Leeuwen et al, 1995). Moreover, Rac is essential for Ras-induced
transformation of these cells (Qiu et al, 1995) and in line with
this, Tiam1-deficient mice are resistant to the development of
Ras-induced skin tumours (Malliri et al, 2002). In addition, we
identified several Tiam1 mutations in a significant proportion of
human renal cell carcinomas, one of which proved sufficient to
transform NIH3T3 cells in vitro (Engers et al, 2000). Despite these
functions the potential prognostic relevance of Tiam1 expression
in human tumours has not been investigated yet.
In the present study, we have analysed Tiam1 expression in
benign secretory epithelium, high-grade prostatic intraepithelium
neoplasia (HG-PIN), and prostate carcinomas by semiquantitative
immunohistochemistry. We found that Tiam1 is significantly
overexpressed in almost all prostate carcinomas and HG-PIN
lesions when compared to the corresponding benign secretory
epithelium. Moreover, in multivariate analysis, the extent of Tiam1
overexpression relative to the corresponding benign epithelial cells
proved to be an independent predictor of decreased disease-free
survival (DFS) for patients with prostate cancer.
MATERIALS AND METHODS
Patients
In the present study, we investigated Tiam1 expression by
semiquantitative immunohistochemistry in 60 patients with R0-
resected prostate cancer, who underwent radical prostatectomy at
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sthe University Hospital of Duesseldorf. Mean patient age was
65.75 years (range, 55–79 years; median, 67 years). Patients were
excluded from the study if they had received neoadjuvant
hormonal therapy, if surgical margins were positive, and/or if
postoperative PSA values remained above 0.3ngml
 1. Disease
recurrence was considered in the following circumstances: (a) PSA
measurement above 0.3ngml
 1; (b) radiological or histological
evidence of local recurrence or metastasis. Disease-free survival
was calculated from the date of radical prostatectomy to the date
of recurrence or last follow-up. Appropriate follow-up data were
available for 53 patients. Of these, one patient died from prostate
cancer, seven died from other diseases and 36 were censored.
Median follow-up time of survivors was 7.2 years (range,
2–14.4 years). Mean preoperative PSA levels were
14.4712ngml
 1 (range, 1.2–60.5ngml
 1). For one patient the
preoperative PSA level was unknown. The study performance was
approved by the ethics committee of the Heinrich-Heine-
University of Duesseldorf.
Pathological and immunohistochemical evaluation
All tumours were staged using the Tumour-Node-Metastasis
(TNM) system (Sobin and Wittekind, 2002) and graded according
to the system described by Gleason (1988). Moreover, all tumours
were evaluated for blood vessel invasion (BVI), lymph vessel
invasion (LVI), perineural invasion (PNI), and the presence of HG-
PIN by the study pathologist. For immunohistochemistry repre-
sentative 5-mm sections of paraffin-embedded tissue specimens
were subjected to heat-induced antigen retrieval and subsequently
incubated with a Tiam1-specific rabbit polyclonal antibody (anti-
DH, (Habets et al, 1994; Malliri et al, 2002, 2006) dilution 1:100)
using a Ventana BenchMark immunohistochemical autostainer
(Ventana Medical Systems, Munich, Germany) including the
respective solutions according to the manufacturer’s instructions.
As a negative control, representative sections were subjected to the
same immunostaining procedure except for the fact that the
primary antibody was omitted. As a positive control, paraffin-
embedded tumour spheroids of Tiam1-transfected renal carcino-
ma cells (Engers et al, 2001) were used. The specificity of the
Tiam1 antibody used in this study has previously been demon-
strated (Habets et al, 1994; Malliri et al, 2002). For quantification,
the percentage of positive cells was divided into five groups: 0, 0%;
1, 1–10%; 2, 11–50%; 3, 51–80%; and 4, 480%. Moreover, a scale
from 0 (no staining) to 3 (strong immunoreactivity) was assigned
to staining intensity. Immunoreactive scores (range, 0–12) were
calculated by multiplying percentage score of positive cells times
staining intensity score (Beck et al, 1994). This scoring system was
used, because it is well established in routine diagnostic pathology.
In order to exclude potential influences of unknown differences
in tissue fixation on immunohistochemical results, the extent of
Tiam1 overexpression in prostate cancer relative to the corre-
sponding normal tissue was used for statistical analyses rather
than absolute immunoreactive scores. As in all cases analysed
immunoreactive scores in benign secretory epithelial cells were
X1, the extent of Tiam1 overexpression was calculated as ratio of
Tiam1 immunoreactive scores in prostate carcinoma or HG-PIN,
respectively, relative to Tiam1 immunoreactive scores in the
corresponding benign secretory epithelium in the same section.
Slides were scored without knowledge of clinico-pathologic or
disease outcome variables.
Statistics
Tiam1 expression in benign, preneoplastic (HG-PIN), and
neoplastic lesions was compared by the Wilcoxon test. Associa-
tions between Tiam1 overexpression and different clinico-patho-
logical parameters were assessed with Fisher’s exact test. The data
on various biochemical and pathological parameters as well as
Tiam1 expression were analysed by Cox proportional hazard
method, using single variable analysis (univariate analysis) or step-
wise selection (multivariate) analysis. Stratified Kaplan–Meier
analyses were performed on the variables that were found to be
significant in the Cox proportional hazard model. All P-values
were two-sided. The analyses were performed with SPSS statistical
software version 12.0 (SPSS GmbH, Munich, Germany).
RESULTS
Histological tumour characterisation
Based on histological examination 37 tumours (62%) were
categorised as pT2 (organ-confined tumours) and 23 tumours
(38%) as pT3 (tumours with extraprostatic extension). In one
patient (2%) a single lymph node micrometastasis was observed.
All patients were free of distant metastases at the time of radical
prostatectomy. Gleason scores ranged from 5 to 10 with GS o7i n
11 patients (18%) and GS X7 in 49 patients (82%). PNI was
observed in 46 patients (77%), LVI in six patients (10%), and BVI
in two patients (3%).
Tiam1 is significantly stronger expressed in high-grade
prostatic intraepithelium neoplasia lesions and prostate
carcinomas than in the corresponding benign prostatic
glands
By semiquantitative immunohistochemistry significant differences
in Tiam1 expression became evident between benign prostatic
glands on the one hand and HG-PIN lesions and prostate cancer
on the other hand. Thus, Tiam1 proved significantly stronger
expressed in 54 out of 55 (98.2%) HG-PIN lesions than in the
respective normal counterpart (Po0.001) (Figure 1A and C).
Similarly 58 out of 60 (96.7%) prostate carcinomas exhibited
significantly stronger Tiam1 expression levels than the respective
benign secretory epithelium (Po0.001) (Figure 1B and C). On
average, Tiam1 expression levels were 3.75-fold higher in prostate
cancer and 3.6-fold higher in HG-PIN lesions, respectively, than in
the corresponding benign secretory epithelial cells (Figure 1C).
However, no difference was seen between Tiam1 expression in
prostate cancer and HG-PIN lesions (Figure 1C). In general Tiam1
expression in prostate cancer was very homogeneous and did not
differ between different Gleason patterns or different tumour foci
on the same slide.
In addition to significant differences in Tiam1 expression
between benign and premalignant (i.e. HG-PIN) or benign and
malignant prostatic epithelial cells (i.e. cancer), respectively, we
also observed differences in Tiam1 expression between normal
non-epithelial cells, including inflammatory cells, fibromuscular
stromal cells, and ganglion cells. Although semiquantitative
analysis was not applied to these cell types, we constantly observed
that amongst the inflammatory cells Tiam1 expression was
markedly stronger in plasma cells than in lymphocytes and
histiocytes, and that neutrophilic granulocytes appeared to be
negative (Figure 1D). Moreover, Tiam1 was strongly expressed by
ganglion cells (Figure 1E), whereas fibromuscular stromal cells
failed to express Tiam1 (Figure 1A and B).
Evaluating potential associations between Tiam1 protein
expression in prostate cancer and different clinico-
pathological factors
To analyse potential associations between the extent of Tiam1
overexpression in prostate cancer and different clinico-pathologi-
cal factors (age, preoperative PSA, LVI, BVI, PNI, pT, pN, GS,
and disease recurrence) Tiam1 immunoreactive ratios (e.g.
Tiam1 expression levels in prostate cancer relative to those
in the corresponding benign secretory epithelial cells), were
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sdichotomised into two categories (o3.5-fold vs X3.5-fold). The
cutoff level of 3.5-fold rather than 3.75-fold (the latter of which
represents the mean extent of Tiam1 overexpression in our cohort)
was chosen for two reasons: (i) 3.5-fold is more convenient in
terms of a potential application in routine pathology and (ii) only
one patient was affected by this modification. Given a mean
preoperative PSA level of 14.4ngml
 1 in our cohort, preoperative
PSA levels were dichotomised into o15 vs X15ngml
 1. Gleason
scores was subdivided into o7 vs X7, and pT stage into organ-
confined tumours (pT2) vs tumours with extraprostatic extension
(pT3). Other parameters such as LVI, BVI, PNI, and pN were
categorised into present vs not present. As shown in Table 1, the
extent of Tiam1 overexpression in prostate carcinoma was
statistically significantly associated with the presence of LVI
(P¼0.031), GS X7( P¼0.044) and with disease recurrence
(P¼0.016), but not with any other parameter.
Evaluating the prognostic relevance of Tiam1
overexpression and different clinico-pathological factors in
prostate cancer
Univariate analysis As the patients in this cohort had variable
follow-up times between 24 and 173 months, the Cox proportional
hazards model and single-parameter analysis was used to
determine the prognostic significance of each of the different
clinico-pathological factors (i.e. age, preoperative PSA, LVI, BVI,
PNI, pT, pN, and GS) as well as Tiam1 overexpression. As shown
in Table 2, age, LVI, BVI, PNI, and pN did not significantly predict
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Figure 1 Immunohistochemical analysis of Tiam1 protein expression in human prostate cancer patients. Tiam1 expression was strongly increased in
preneoplastic HG-PIN lesions (A) and prostate cancer (Ca) (B) as compared to adjacent benign secretory epithelium (Normal). Please note that
fibromuscular stromal cells (FMS) were negative for Tiam1 expression. (C) Comparison of Tiam1 expression levels (mean7s.d.) in benign secretory
epithelium (n¼60), HG-PIN lesions (n¼55), and prostate cancer (n¼60) as determined by semiquantitative immunohistochemistry. Tiam1 expression
levels were significantly higher in prostate cancer and HG-PIN lesions than in benign secretory epithelium (two-sided Wilcoxon test). (D) Tiam1 expression
in inflammatory cells of prostate cancer patients. Tiam1 was strongly expressed in plasma cells (P) and weakly expressed in lymphocytes (L) and histiocytes
(H). In contrast, neutrophilic granulocytes (N) proved to be negative. Moreover, Tiam1 was weakly expressed in adjacent benign epithelial cells (BE). (E)I n
addition to prostate cancer (Ca), strong Tiam1 expression was also seen in ganglion cells (G) adjacent to the prostate, whereas lymphocytes (L) exhibited
only low Tiam1 expression levels. Original magnifications: (A)  250; (B)  100; (D)  400; (E)  200.
Tiam1 overexpression in prostate cancer
R Engers et al
1083
British Journal of Cancer (2006) 95(8), 1081–1086 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sDFS. In contrast the extent of Tiam1 overexpression (X3.5-fold vs
o3.5-fold) (P¼0.03), preoperative PSA level (P¼0.044), pT stage
(P¼0.006), and GS (P¼0.001) significantly predicted decreased
DFS. More specifically, the mean DFS time of patients with strong
Tiam1 overexpression (X3.5-fold) in prostate carcinomas was
98 months (95% confidence interval (CI)¼77–119), whereas the
mean DFS time of patients with weak Tiam1 overexpression
(o3.5-fold) was 136 months (95% CI¼118–154).
Multivariate analysis To determine the smallest number of
parameters that could jointly predict disease recurrence in our
cohort of patients, the Cox proportional hazard model and step-
wise selection analysis was used. When all parameters with
significant prognostic impact in univariate analysis (i.e. preopera-
tive PSA, pT stage, GS, and the extent of Tiam1 overexpression)
were included in the model, only pT stage (P¼0.028, hazard
ratio¼4.61), GS (P¼0.019, hazard ratio¼1.80), and the extent
of Tiam1 overexpression (P¼0.04, hazard ratio¼3.75) reached
statistical significance in predicting decreased DFS (Table 3).
Moreover, including the extent of Tiam1 overexpression in the
analysis further classified the pT stage and GS groups into high-
and low-risk patients. To demonstrate the joint effects of Tiam1
overexpression and pT stage or Tiam1 overexpression and GS,
respectively, on disease recurrence, Kaplan–Meier analysis was
performed. As shown in Figure 2A, in both pT stage subgroups
(pT2 and pT3) patients with strong Tiam1 overexpression (i.e.
X3.5-fold) had a significantly worse prognosis than patients
with weak Tiam1 overexpression (i.e. o3.5-fold) (Po0.001). Thus,
the highest probability of disease recurrence was found in
patients with strong Tiam1 overexpression and pT3 stage, whereas
individuals with weak Tiam1 overexpression and pT2 stage had the
lowest probability of recurrence. Likewise, when the cohort was
stratified into GS o7 vs GS X7, patients with strong Tiam1
overexpression and GS X7 had the highest probablility of disease
recurrence, followed by patients with weak Tiam1 overexpression
and GS X7 (Figure 2B). The least probability of disease recurrence
was found in the subgroup of GS o7. This subgroup, however, was
restricted to 11 patients and no disease recurrence was observed
during a median follow-up time of 72 months (range, 36–135
months). Thus, in the subgroup of GS o7 a prognostic impact of
Tiam1 overexpression could not be established, at least not for the
restricted number of patients and the given mean follow-up time.
DISCUSSION
In the present study, we show for the first time that in almost all
prostate carcinomas the Tiam1 protein is significantly stronger
expressed than in the corresponding benign prostate epithelial
cells. In addition, strong Tiam1 overexpression (i.e. X3.5-fold) in
prostate cancer relative to the corresponding benign epithelial cells
is statistically significantly associated with decreased DFS after
radical prostatectomy both in univariate analysis and in multi-
variate analysis, including several factors typically used to predict
the prognosis of patients with prostate cancer. Therefore, our
results suggest that strong Tiam1 overexpression is a new and
Table 1 Clinicopathologic features of Tiam1 overexpression in prostate
cancer
a
Tiam1
overexpression o3.5
Tiam1
overexpression X3.5
Factor (n¼26) No. (%) (n¼34) No. (%) P-value
b
Age (y)
o65 13 (22) 13 (22) 0.435
X65 13 (22) 21 (35)
Preoperative PSA
c (ngml
 1)
o15 18 (31) 19 (32) 0.423
X15 8 (14) 14 (24)
Disease recurrence
d
No 20 (38) 16 (30) 0.016*
Yes 3 (6) 14 (26)
LVI
No 26 (43) 28 (47) 0.031*
Yes 0 (0) 6 (10)
BVI
No 25 (42) 33 (55) 1.0
Yes 1 (2) 1 (2)
PNI
No 6 (10) 8 (13) 1.0
Yes 20 (33) 26 (43)
pT
pT2 18 (30) 19 (32) 0.422
pT3 8 (13) 15 (25)
pN
pN0 26 (43) 33 (55) 1.0
pN1 0 (0) 1 (2)
GS
o7 8 (13) 3 (5) 0.044*
X7 18 (30) 31 (52)
BVI: blood vessel invasion; GS: Gleason score; LVI: lymph vessel invasion; PNI:
perineural invasion; PSA, prostate-specific antigen; y, years. *Statistically significant.
aBecause of rounding percentages may not equal 100%.
bFisher’s exact test, two
sided.
cPreoperative PSA levels were available for 59 out of 60 patients.
dAppropriate
follow-up was available for 53 out of 60 patients.
Table 2 Univariate analysis of pre- and postoperative parameters as well
as Tiam1 overexpression
Parameter v
2 P-value Hazard ratio 95% CI
Age 1.658 0.202 1.058 0.970–1.155
Preoperative PSA 4.174 0.044* 1.035 1.001–1.070
pT 9.451 0.006* 5.805 1.657–20.339
pN 3.726 0.091 6.098 0.750–50
GS 12.685 0.001* 2.121 1.369–3.286
PNI 2.105 0.164 2.907 0.646–13.158
BVI 0.592 0.612 21.639 0.000–3126101
LVI 2.323 0.142 2.604 0.725–9.346
Tiam1 overexpression 5.531 0.030* 4 1.15–13.89
CI, confidence interval. *Statistically significant. Cox proportional hazard model and
single parameter analysis was used to determine the prognostic significance of age,
preoperative PSA, LVI (+/ ), BVI (+/ ), PNI (+/ ), pT stage (pT3/pT2), pN stage
(pN1/pN0), GS, and Tiam1 overexpression (X3.5-fold/o3.5-fold). Age, preopera-
tive PSA and GS were used as continuous variables.
Table 3 Multivariate analysis of Tiam1 overexpression with disease
recurrence in patients with prostate cancer by the Cox proportional hazard
method
Variable P-value* HR (95% CI)*
Tiam1 overexpression (X3.5 vs o3.5-fold) 0.040 3.75 (1.06–13.16)
pT (pT3 vs pT2) 0.028 4.61 (1.18–18.18)
GS 0.019 1.80 (1.10–2.96)
Preoperative PSA 0.134 1.03 (0.99–1.08)
CI, confidence interval; GS: Gleason score; HR, hazard ratio; PSA, prostrate-specific
antigen. *All statistical tests were two sided. Preoperative PSA and GS were used as
continuous variables.
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prostate cancer and that tumours with strong Tiam1 overexpres-
sion require more aggressive treatment.
The cohort of our study is restricted to 60 patients with prostate
cancer, including 53 patients with appropriate follow-up. Despite
its limited size, the strength of this cohort is its restriction to R0-
resected tumours, because thus disease recurrence indeed reflects
tumour aggressiveness (i.e. the development of metastasis) rather
than being merely the result of incomplete surgical excision of the
primary tumour. Furthermore, our cohort is representative, as
evidenced by the fact that well-established prognostic factors,
including preoperative PSA level, pT stage, and GS, also
significantly predicted disease recurrence in our study. Of these,
only preoperative PSA lost its prognostic impact in multivariate
analysis, when combined with the extent of Tiam1 overexpression
in prostate cancer. Thus, the smallest number of parameters that
could jointly predict disease recurrence included pT stage, GS, and
the extent of Tiam1 overexpression. Moreover, Kaplan–Meier
analysis showed that prostate cancer patients with pT3 stage and
GSX7, respectively, could be further classified based on the extent
of Tiam1 overexpression in their prostate cancer specimens to
predict disease recurrence more accurately. Only in the subgroup
of GSo7 a prognostic effect of the extent of Tiam1 overexpression
could not be established despite a mean follow-up time of 6 years.
This, however, does not exclude a prognostic relevance of the
extent of Tiam1 overexpression in this subgroup. It has been
shown that the overall postoperative risk of patients with GSo7
tumours to develop disease recurrence at 5 years is only about 1–
2% (Epstein et al, 1996). Consequently, the mean follow-up time of
6 years and the number of patients (n¼11) in the GSo7 subgroup
of our cohort are not likely to be sufficient to allow the detection
of new prognostic markers in this subgroup. So far, we have
evaluated Tiam1 expression only in radical prostatectomy speci-
mens, but if this marker is to be used as part of a pretreatment
decision-making tool, its predictive power has to be validated in
studies on biopsy specimens as well.
Increased Tiam1 expression was observed in almost all prostate
carcinomas when compared to the corresponding benign epithelial
cells and the distribution of Tiam1 staining is reminiscent of
that reported for alpha-methyl CoA racemase (Jiang et al, 2001;
Zhou et al, 2004). In contrast to alpha-methyl CoA racemase,
Tiam1 expression was seen in benign glands more regularly,
but expression levels were usually low and only a fraction of
benign epithelial cells was positive. This suggests that similar
as reported for alpha-methyl CoA racemase, strong Tiam1
expression could be used as an adjunct for the diagnosis of
prostate cancer in difficult cases such as small foci in prostate
needle biopsies. Nevertheless, further studies on biopsy specimens
are required to finally evaluate the diagnostic potential of strong
Tiam1 expression in resolving an atypical diagnosis on prostate
needle biopsies.
Interestingly, significantly increased Tiam1 expression levels
were not only observed in prostate cancer, but also in almost all
preneoplastic HG-PIN lesions, indicating that increased Tiam1
expression occurs early in prostate carcinoma development.
Although the molecular mechanism, causing increased Tiam1
expression in HG-PIN lesions and prostate cancer, has yet to be
determined, there are indications that it might result at least in
part from increased Wnt/b-catenin signaling. The Wnt/b-catenin
signaling pathway plays a central role in colon cancer development
(for review see Oving and Clevers (2002)), but in several studies
aberrant activation of Wnt/b-catenin signaling has also been
implicated in the formation of PIN-like proliferative lesions as
well as in prostate cancer progression (for review see Mimeault
and Batra (2006); Yardy and Brewster (2005)). Interestingly, we
recently identified Tiam1 as a Wnt-responsive gene that is
upregulated in intestinal and colon tumours, and by comparing
tumour development in APC mutant multiple intestinal neoplasia
(Min) mice expressing or lacking Tiam1, we found that Tiam1
deficiency significantly reduces the formation and growth of
intestinal polyps in vivo (Malliri et al, 2006). Given these results
and the established oncogenic/transforming potentials of Tiam1
and its downstream target Rac in other cell types, one might
speculate that a cross-talk between Wnt/b-catenin and Tiam1-Rac
signaling plays a major role in the development of prostate cancer,
although the underlying molecular mechanism remains to be
determined. Tiam1 and Rac stimulate several important signaling
pathways, including the p38 mitogen-activated protein kinase (p38
MAPK), the c-Jun N-terminal kinase, and the extracellular signal-
regulated kinase pathways (Coso et al, 1995; Zhang et al, 1995;
Frost et al, 1996), which are known to regulate gene transcription.
Therefore, it is conceivable that increased Tiam1 expression
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Figure 2 Kaplan–Meier analysis was performed after stratifying the data (A) as pT2 (organ-confined tumours)/pT3 (tumours with extraprostatic
extension) and Tiam1 strong (s)/weak (w) and (B)a sG So7/X7 and Tiam1 strong (s)/weak (w). Statistical analysis was performed by means of the
two-sided log-rank test.
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smight induce transcription of distinct oncogenes and/or inhibit
transcription of distinct tumour suppressor genes, which conse-
quently contributes to oncogenic transformation.
In addition to its role in oncogenic transformation, Tiam1 has
also been implicated in the regulation of migration, invasion, and
metastasis of tumour cells (Habets et al, 1994; Hordijk et al, 1997;
Adam et al, 2001; Engers et al, 2001). Interestingly, the effects of
Tiam1 on migration and invasion in vitro may be either
stimulating or inhibitory, depending on the cell-substrate used,
the fact as to whether or not the formation of E-cadherin-mediated
cell–cell adhesions is prevented, and the cell type studied (Sander
et al, 1998; Engers et al, 2001; Price and Collard, 2001; Minard et al,
2004). Given these heterogeneous effects of Tiam1 on migration
and invasion of epithelial cells in vitro, the effect of increased
Tiam1 expression in a given tumour in vivo on DFS might be
positive or negative. In prostate cancer we found that strong Tiam1
overexpression (X3.5-fold) relative to the corresponding benign
secretory epithelium is significantly associated with decreased DFS
in univariate and most importantly also in multivariate analysis.
This suggests that in prostate cancer strong Tiam1 overexpression
is a new and independent predictor of tumour aggressiveness. In
line with this a positive correlation has been found between Tiam1
expression levels and a high tumour grade in breast cancer (Adam
et al, 2001). In that study, however, only nine tumour samples have
been analysed.
In conclusion, the present study with up to 14.4-year follow-up
shows that strong Tiam1 overexpression in prostate cancer relative
to the corresponding benign prostate epithelial cells correlates with
aggressive disease and is an independent prognostic indicator of
disease recurrence. Validation of this study involving a relatively
small number of patients will establish the independent prognostic
potential of strong Tiam1 overexpression in predicting disease
recurrence. Moreover, it will be interesting to analyse its predictive
power in further studies on biopsy specimens as well as in other
tumour cell types.
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